HWM
AIMT

HighMark Wealth Management’s Aimmune Therapeutics AIMT Stock Holding History

HighMark Wealth Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31
Closed -$1K – 499
2020
Q3 		$1K Hold
31
– – ﹤0.01% 439
2020
Q2 		$1K Hold
31
– – ﹤0.01% 426
2020
Q1 		$0 Hold
31
– – ﹤0.01% 435
2019
Q4 		$1K Buy
+31
New +$867 ﹤0.01% 386

HighMark Wealth Management's AIMT Position: Q4 2020 in Review

HighMark Wealth Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 31 shares — an estimated $1K sold.

HighMark Wealth Management first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $1K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • HighMark Wealth Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • HighMark Wealth Management sold 31 Aimmune Therapeutics shares in Q4 2020, an estimated $1K.
  • HighMark Wealth Management first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
  • HighMark Wealth Management's Aimmune Therapeutics position peaked at $1K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on HighMark Wealth Management's 13F filing for Q4 2020, filed 27 Jan 2021.